Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fee Negotiations Begin In Ernest On Feb. 28 With Four Seats At The Table

This article was originally published in The Pink Sheet Daily

Executive Summary

Two API manufacturing groups, including a European group, will join GPhA in discussions with FDA.
Advertisement

Related Content

Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected
Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees
Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees

Topics

Advertisement
UsernamePublicRestriction

Register

PS071851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel